TY - JOUR
T1 - Glioblastoma multiforme
T2 - Advances in postsurgical management
AU - Mohin, Geetika
AU - Madajewicz, Stefan
AU - Manzione, James
AU - Franceschi, Dinko
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2006/10
Y1 - 2006/10
N2 - Glioblastoma multiforme (GBM) is the most common and aggressive form of primary brain tumor in adults, striking 8,000 to 10,000 people per year in North America alone. Even under the most favorable circumstances, patients die within the first 2 years of diagnosis. Recent advances in diagnostic imaging, microsurgical techniques, and medical management of this rare malignancy have led to more accurate diagnoses, staging, improvement in quality of life, and overall survival. In this review, the authors briefly summarize the pathogenesis and clinical presentation of GBM and then describe their experience in treating this disease after surgery using intraarterial chemotherapy-itself an unusual and still investigational approach-followed by concomitant radiotherapy and oral temozolomide therapy and then adjuvant maintenance therapy with temozolomide alone.
AB - Glioblastoma multiforme (GBM) is the most common and aggressive form of primary brain tumor in adults, striking 8,000 to 10,000 people per year in North America alone. Even under the most favorable circumstances, patients die within the first 2 years of diagnosis. Recent advances in diagnostic imaging, microsurgical techniques, and medical management of this rare malignancy have led to more accurate diagnoses, staging, improvement in quality of life, and overall survival. In this review, the authors briefly summarize the pathogenesis and clinical presentation of GBM and then describe their experience in treating this disease after surgery using intraarterial chemotherapy-itself an unusual and still investigational approach-followed by concomitant radiotherapy and oral temozolomide therapy and then adjuvant maintenance therapy with temozolomide alone.
UR - http://www.scopus.com/inward/record.url?scp=33845611541&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845611541&partnerID=8YFLogxK
U2 - 10.1016/S1548-5315(11)70921-4
DO - 10.1016/S1548-5315(11)70921-4
M3 - Review article
AN - SCOPUS:33845611541
VL - 3
SP - 678
EP - 683
JO - Community Oncology
JF - Community Oncology
SN - 1548-5315
IS - 10
ER -